

HR 4385

Cancer Drug Parity Act of 2021

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: Jul 9, 2021

Current Status: Referred to the House Committee on Education and Labor.

Latest Action: Referred to the House Committee on Education and Labor. (Jul 9, 2021)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/4385>

Sponsor

Name: Rep. Higgins, Brian [D-NY-26]

Party: Democratic • **State:** NY • **Chamber:** House

Cosponsors (36 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Bilirakis, Gus M. [R-FL-12]	R · FL		Jul 9, 2021
Rep. Grothman, Glenn [R-WI-6]	R · WI		Jul 9, 2021
Rep. Guthrie, Brett [R-KY-2]	R · KY		Jul 9, 2021
Rep. Matsui, Doris O. [D-CA-6]	D · CA		Jul 9, 2021
Rep. Morelle, Joseph D. [D-NY-25]	D · NY		Jul 9, 2021
Rep. Case, Ed [D-HI-1]	D · HI		Sep 10, 2021
Rep. Wild, Susan [D-PA-7]	D · PA		Oct 5, 2021
Rep. McBath, Lucy [D-GA-6]	D · GA		Oct 20, 2021
Rep. Clarke, Yvette D. [D-NY-9]	D · NY		Oct 22, 2021
Rep. Panetta, Jimmy [D-CA-20]	D · CA		Oct 28, 2021
Rep. Blumenauer, Earl [D-OR-3]	D · OR		Nov 18, 2021
Rep. Bonamici, Suzanne [D-OR-1]	D · OR		Nov 18, 2021
Rep. Brownley, Julia [D-CA-26]	D · CA		Nov 18, 2021
Rep. Maloney, Carolyn B. [D-NY-12]	D · NY		Nov 18, 2021
Rep. Suozzi, Thomas R. [D-NY-3]	D · NY		Nov 18, 2021
Rep. Trone, David J. [D-MD-6]	D · MD		Dec 7, 2021
Rep. Connolly, Gerald E. [D-VA-11]	D · VA		Jan 11, 2022
Rep. Young, Don [R-AK-At Large]	R · AK		Jan 11, 2022
Rep. Davis, Rodney [R-IL-13]	R · IL		Feb 1, 2022
Rep. Fitzpatrick, Brian K. [R-PA-1]	R · PA		Feb 1, 2022
Rep. Pingree, Chellie [D-ME-1]	D · ME		Feb 1, 2022
Rep. Yarmuth, John A. [D-KY-3]	D · KY		Feb 1, 2022
Rep. Allred, Colin Z. [D-TX-32]	D · TX		Feb 8, 2022
Rep. Wittman, Robert J. [R-VA-1]	R · VA		Feb 18, 2022
Rep. Bost, Mike [R-IL-12]	R · IL		Jul 13, 2022
Rep. Barragan, Nanette Diaz [D-CA-44]	D · CA		Jul 29, 2022
Rep. Burgess, Michael C. [R-TX-26]	R · TX		Sep 21, 2022
Rep. Cleaver, Emanuel [D-MO-5]	D · MO		Sep 21, 2022
Rep. Napolitano, Grace F. [D-CA-32]	D · CA		Sep 21, 2022
Rep. Aguilar, Pete [D-CA-31]	D · CA		Sep 28, 2022
Rep. Castor, Kathy [D-FL-14]	D · FL		Sep 28, 2022
Rep. Kuster, Ann M. [D-NH-2]	D · NH		Oct 7, 2022
Rep. Malinowski, Tom [D-NJ-7]	D · NJ		Oct 28, 2022
Rep. Raskin, Jamie [D-MD-8]	D · MD		Nov 7, 2022
Rep. Evans, Dwight [D-PA-3]	D · PA		Nov 14, 2022
Rep. Lowenthal, Alan S. [D-CA-47]	D · CA		Nov 14, 2022

Committee Activity

Committee	Chamber	Activity	Date
Education and Workforce Committee	House	Referred To	Jul 9, 2021

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
117 S 3080	Identical bill	Oct 27, 2021: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Summary (as of Jul 9, 2021)

Cancer Drug Parity Act of 2021

This bill requires group health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications. This requirement applies to medications that are (1) approved by the Food and Drug Administration; (2) medically necessary for the cancer treatment; and (3) clinically appropriate in terms of type, frequency, extent site, and duration.

To comply with this requirement, plans may not, with respect to anticancer medications (1) change or replace benefits to increase out-of-pocket costs, (2) reclassify benefits to increase costs, or (3) apply more restrictive limitations to orally administered medications than to intravenously administered or injected medications.

Actions Timeline

- Jul 9, 2021: Introduced in House
- Jul 9, 2021: Referred to the House Committee on Education and Labor.